Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic
Laith J. Abu‐Raddad, Hiam Chemaitelly, Houssein H. Ayoub, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 143

Showing 1-25 of 143 citing articles:

Infection fatality rate of COVID-19 inferred from seroprevalence data
John P. A. Ioannidis
Bulletin of the World Health Organization (2020) Vol. 99, Iss. 1, pp. 19-33F
Open Access | Times Cited: 565
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
Hiam Chemaitelly, Patrick Tang, Mohammad R. Hasan, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 24
Open Access | Times Cited: 553
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
Heba N. Altarawneh, Hiam Chemaitelly, Houssein H. Ayoub, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 1, pp. 21-34
Open Access | Times Cited: 475
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
Patrick Tang, Mohammad R. Hasan, Hiam Chemaitelly, et al.
Nature Medicine (2021) Vol. 27, Iss. 12, pp. 2136-2143
Open Access | Times Cited: 416
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
Hiam Chemaitelly, Hadi M. Yassine, Fatiha M. Benslimane, et al.
Nature Medicine (2021) Vol. 27, Iss. 9, pp. 1614-1621
Closed Access | Times Cited: 394
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
Laith J. Abu‐Raddad, Hiam Chemaitelly, Houssein H. Ayoub, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 19, pp. 1804-1816
Open Access | Times Cited: 362
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
Hiam Chemaitelly, Houssein H. Ayoub, Sawsan AlMukdad, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 214
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy
Laith J. Abu‐Raddad, Hiam Chemaitelly, Peter Coyle, et al.
EClinicalMedicine (2021) Vol. 35, pp. 100861-100861
Open Access | Times Cited: 173
Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting
Laith J. Abu‐Raddad, Hiam Chemaitelly, Joel A. Malek, et al.
Clinical Infectious Diseases (2020) Vol. 73, Iss. 7, pp. e1830-e1840
Open Access | Times Cited: 165
Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar
Laith J. Abu‐Raddad, Hiam Chemaitelly, Houssein H. Ayoub, et al.
JAMA (2021) Vol. 326, Iss. 19, pp. 1930-1930
Open Access | Times Cited: 161
COVID-19 (SARS-CoV-2) outbreak monitoring using wastewater-based epidemiology in Qatar
Jayaprakash Saththasivam, Shimaa S. El-Malah, Tricia Gomez, et al.
The Science of The Total Environment (2021) Vol. 774, pp. 145608-145608
Open Access | Times Cited: 144
Reconciling estimates of global spread and infection fatality rates of COVID‐19: An overview of systematic evaluations
John P. A. Ioannidis
European Journal of Clinical Investigation (2021) Vol. 51, Iss. 5
Open Access | Times Cited: 120
Coronavirus Disease 2019 Disease Severity in Children Infected With the Omicron Variant
Adeel A. Butt, Soha R. Dargham, Srusvin Loka, et al.
Clinical Infectious Diseases (2022) Vol. 75, Iss. 1, pp. e361-e367
Open Access | Times Cited: 117
Severity of Illness in Persons Infected With the SARS-CoV-2 Delta Variant vs Beta Variant in Qatar
Adeel A. Butt, Soha R. Dargham, Hiam Chemaitelly, et al.
JAMA Internal Medicine (2021) Vol. 182, Iss. 2, pp. 197-197
Open Access | Times Cited: 101
Duration of immune protection of SARS-CoV-2 natural infection against reinfection
Hiam Chemaitelly, Nico Nagelkerke, Houssein H. Ayoub, et al.
Journal of Travel Medicine (2022) Vol. 29, Iss. 8
Open Access | Times Cited: 90
Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections
Laith J. Abu‐Raddad, Hiam Chemaitelly, Houssein H. Ayoub, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 70
Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study
Hiam Chemaitelly, Houssein H. Ayoub, Patrick Tang, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 7, pp. 816-827
Open Access | Times Cited: 70
Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage
Hiam Chemaitelly, Houssein H. Ayoub, Peter Coyle, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 67
Graphene oxide@Fe3O4-decorated iota-carrageenan composite for ultra-fast and highly efficient adsorption of lead (II) from water
Ahmed M. Omer, Mohamed A. El-Sayed, Eman M. Abd El-Monaem, et al.
International Journal of Biological Macromolecules (2023) Vol. 253, pp. 127437-127437
Closed Access | Times Cited: 45
Recent advances in chitosan-based nanocomposites for adsorption and removal of heavy metal ions
Mohammad Saeid Rostami, Mohammad Mehdi Khodaei
International Journal of Biological Macromolecules (2024) Vol. 270, pp. 132386-132386
Closed Access | Times Cited: 15
Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron
Hiam Chemaitelly, Houssein H. Ayoub, Peter Coyle, et al.
Nature (2025)
Open Access | Times Cited: 2
SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals
Peter Coyle, Hiam Chemaitelly, Mohamed Ali Ben Hadj Kacem, et al.
iScience (2021) Vol. 24, Iss. 6, pp. 102646-102646
Open Access | Times Cited: 89
Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar
Andrew Jeremijenko, Hiam Chemaitelly, Houssein H. Ayoub, et al.
Emerging infectious diseases (2021) Vol. 27, Iss. 5, pp. 1343-1352
Open Access | Times Cited: 88
Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19
Houssein H. Ayoub, Hiam Chemaitelly, Shaheen Seedat, et al.
Journal of Global Health (2021) Vol. 11
Open Access | Times Cited: 86
SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar
Mohamed H. Al‐Thani, Elmoubasher Farag, Roberto Bertollini, et al.
Open Forum Infectious Diseases (2021) Vol. 8, Iss. 8
Open Access | Times Cited: 76
Page 1 - Next Page

Scroll to top